Effect of Schisandra chinensis (Turcz) Schisandraceae seed extracts and cisplatin on cytotoxicity, genotoxicity and wound healing in MCF-7 cells
Purpose: Schisandra chinensis is a plant used in traditional Chinese and Russian medicine. An S. chinensis seed extract was tested for its ability to potentiate the effects of the anticancer agent cisplatin in MCF-7 breast cancer cells.
Methods: S. chinensis seeds were extracted with ethanol and the ethanol was evaporated from the extracts to obtain an aqueous fraction of the S. chinensis seed extract (SCSE). MCF-7 cells were exposed to cisplatin alone or in combination with various concentrations of SCSE. The end points that were measured were cytotoxicity, genotoxicity, and wound healing.
Results: The addition of 10 % SCSE increased the cytotoxicity of cisplatin by increasing MCF-7 cell death by 7 %. The combination of 20 % SCSE and cisplatin completely inhibited wound healing in MCF7 cells. SCSE alone did not induce DNA fragmentation in MCF-7 cells.
Conclusion: Compounds from S. chinensis seed extracts may mitigate cancer cell proliferation and migration.
Keywords: Schisandra chinensis, MCF-7 cells, Cytotoxicity, Genotoxicity, Wound healing, Cisplatin
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.